Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Guided Therapeutics reports positive findings from cancer detection study
Based on the outcome of the study, Guided Therapeutics (GT) plans to submit the trial results to the FDA as part of the premarket approval (PMA) application for
Based on the outcome of the study, Guided Therapeutics (GT) plans to submit the trial results to the FDA as part of the premarket approval (PMA) application for
The Phase I clinical trial is designed to assess the safety, tolerability and pharmacokinetics of IB1001 in patients with hemophilia B, compared with the commercially available recombinant Factor
Mr Altmeyer succeeds interim president and CEO of Otsuka America Pharmaceutical, Dean Haubrich, who has been leading the company since August 1, 2008 and has been named chairman
According to the company, the ViralClyns P95 respirator has shown to be 100 times more effective than other respirators in its class, stopping 99.99% of airborne and droplet
Under the terms of the agreement, Merck, through an affiliate, will pay Insmed $130 million in cash to acquire all rights to the Boulder facilities and Insmed’s pipeline
The Celerus Wave System is said to be the first and only solution to deliver precise, standardized histology and cytology results in 15 minutes. Intra-operative frozen tissue sections
Mr Joubert is currently a founding partner of EdgeAdvisors, a privately held management consulting organization, and a director of Stream Global Services, a provider of multi-shore business process
Mr Gionco has spent more than 18 years in the pharmaceutical industry, including the past three years with Savient where he most recently served as vice president of
In connection with the financing, the company issued to the investors convertible promissory notes in the aggregate principal amount of $3.24 million and warrants to purchase an aggregate
Teva has completed enrollment for the first of its two Phase III clinical trials for laquinimod (Allegro) in November 2008 and is currently enrolling relapsing-remitting multiple sclerosis (RRMS)